Skip to main content
. 2023 Mar 28;165(5):1389–1400. doi: 10.1007/s00701-023-05533-6

Fig. 1.

Fig. 1

Study enrollment. Schematic overview of the screening, enrollment, and follow-up of the study participants. *Poor performance: Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) > 2 or Karnofsky Performance Status (KPS) < 70